
|Videos|July 31, 2020
Targeted Therapy in Early-Stage HER2+ Breast Cancer
Author(s)Targeted Oncology
Experts from Sarah Cannon Research Institute talk about the expanding role of targeted treatment options in early HER2+ breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dual BCMA/CD19 CAR T, AZD0120, Yields 96% ORR in Myeloma; Fast Turnaround
2
Linvoseltamab Monotherapy Effective in Newly Diagnosed Multiple Myeloma
3
NCCN Guidelines in nccRCC Weigh New Data for Combinations
4
Subcutaneous Cevostamab Shows Early Promise in R/R Myeloma
5








































